Genitope reiterated at sector perform

RBC Capital Markets analyst Jason Kantor reiterated Genitope Corp. at sector perform, speculative risk. The company's ongoing phase 3 trial for MyVax, a vaccine for follicular lymphoma, failed to demonstrate a statistically significant efficacy advantage over a placebo at two interim analyses. The analyst remains cautiously optimistic that the final analysis, expected in late 2007, will demonstrate an advantage over a placebo. Shares of the Redwood City, Calif.-based biotechnology company were down 10 cents, or 3.89%, at $2.47 on volume of 348,640 shares versus the three-month running average of 523,675 shares. (Nasdaq: GTOP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.